Search results for "Highlights"


 
Results 111 - 120 of about 234 for "Highlights".
Sort by: Relevance | Newest | Oldest

Infliximab or tofacitinib for IBD associated with lower response to COVID-19 vaccination

An industry-funded study in England looked at SARS-CoV-2 antibody concentrations after two vaccine doses among patients taking infliximab, tofacitinib, thiopurine, ustekinumab, or vedolizumab for inflammatory bowel disease (IBD), comparing them to healthy controls.
https://gastroenterology.acponline.org/archives/2022/02/25/1.htm
25 Feb 2022

PPIs not associated with mortality risk for most causes, study finds

While patients who took proton-pump inhibitors (PPIs) had significantly higher risks of all-cause mortality and mortality due to cancer, cardiovascular diseases, respiratory diseases, and digestive diseases, lag times of up to six years attenuated these associations so they were no longer statistically significant.
https://gastroenterology.acponline.org/archives/2022/07/22/1.htm
22 Jul 2022

Transportation, patient education among factors affecting colonoscopy rates after abnormal FIT, survey finds

Primary care physicians and staff were asked to identify patients' barriers to completing colonoscopy after an abnormal fecal immunochemical test (FIT) result, as well as factors that made completion more likely.
https://gastroenterology.acponline.org/archives/2021/08/27/2.htm
27 Aug 2021

Education for patients reduced upper GI endoscopies for uninvestigated dyspepsia

To reduce overuse, a Dutch trial provided a self-managed, web-based educational intervention containing information on gastric function, dyspepsia, and upper GI tract endoscopy to some patients referred for the procedure by their primary care clinicians.
https://gastroenterology.acponline.org/archives/2021/05/28/3.htm
28 May 2021

Novel therapy may be effective treatment for H. pylori infection, industry-funded trial finds

About 84% of participants randomly assigned to receive rifabutin in addition to amoxicillin and omeprazole achieved Helicobacter pylori eradication, compared to 58% of those who received amoxicillin and omeprazole alone.
https://gastroenterology.acponline.org/archives/2020/05/22/2.htm
22 May 2020

Tenofovir alafenamide may safely replace tenofovir disoproxil fumarate in patients with drug-resistant HBV, trial finds

An industry-funded randomized trial found that tenofovir alafenamide could be substituted for tenofovir disoproxil fumarate in patients with multidrug-resistant hepatitis B virus (HBV) for improved bone and renal safety without a loss of efficacy; however, the former drug was associated with greater increases in body weight and cholesterol levels.
https://gastroenterology.acponline.org/archives/2021/05/28/4.htm
28 May 2021

Prevalence of liver fibrosis in diabetes suggests need for earlier intervention, study finds

The prevalence of any suspected liver fibrosis in patients with diabetes was 21% in a recent study, leading the authors to call for more aggressive screening in patients with obesity and diabetes.
https://gastroenterology.acponline.org/archives/2021/01/22/3.htm
22 Jan 2021

Half of overweight, obese adults may have fatty liver disease

The global prevalence of metabolic dysfunction-associated fatty liver disease, a newly proposed term for nonalcoholic fatty liver disease, is “astonishingly high,” the authors of a recent meta-analysis found.
https://gastroenterology.acponline.org/archives/2021/02/26/3.htm
26 Feb 2021

GI symptoms associated with better outcomes from COVID-19, new two-part study finds

SARS-CoV-2 was commonly present in the gastrointestinal tract but didn't cause inflammation there, according to a recent analysis of intestinal biopsy tissues from patients with COVID-19.
https://gastroenterology.acponline.org/archives/2021/03/26/2.htm
26 Mar 2021

Practice guidance addresses vascular liver disorders, portal vein thrombosis, procedural bleeding

Among other statements, the American Association for the Study of Liver Diseases said that modifiable risk factors for bleeding, such as use of antithrombotic drugs, should be identified and corrected before procedures in patients with cirrhosis.
https://gastroenterology.acponline.org/archives/2020/12/18/2.htm
18 Dec 2020

Result Page: Prev   7   8   9   10   11   12   13   14   15   16   Next